The American pharmaceutical company Nuvectis Pharma closed all the procedures to create a new drug, NXP900 pill, capable of controlling various types of cancer.
This is a historic milestone in the research of this disease, which emanates from the work of the Spanish scientist Asier Unciti Broceta, director of the Institute of Genetics and the Cancer Laboratory at the University of Edinburgh. Cádiz, sur) in 1976, this discovery is the result of research that began in 2010: “From the beginning we started our research on the SRC protein, which is involved in some types of cancer. discovery in 2015
More in: The Ombudsman asks the Ministry of Health to take urgent measures due to drug shortages. The research led by Unciti added to what was already being done in the scientific community. “When we discovered the inhibitor, there were already inhibitors on the market that were used for leukemia that inhibited other proteins. The difference is that we could never create a drug that worked to fight cancer.” a paradigm shift in the conclusions that had been received up to that time by cancer research worldwide: “What we have learned is that other previous drugs did not do the job of inhibiting the protein. That is why the pharmaceutical industry did not make new ones. What made my pills take so long to arrive, what against we went corn, trying to show what was found was not needed.” This effect led the Edinburgh research team to carry out in recent years preclinical trials in animals: “It stands tumors such as lung, breast, or prostate cancer in many mice.” “Four or five years ago, everyone didn’t even think that was right. We turned around the academic world and now the world’s leading experts in this protein protein are saying that this is the one drug that can finally cure this type of cancer. A paradigm shift has been put in place. Little has happened in science. Hard and the airline had to come like Ninevectis,” he explains. Asier Uniciti represents a pharmaceutical company that has already completed the process of making the NXP900 pill, a definitive step towards a research and milestone application. In the recent history of medicine. To do this, it is necessary to invest more than 30 million dollars. Now, the company is already finalizing the registration of this pill with the Food and Drug Administration of the United States, as well as the process for the introduction of the compound in capsules.
It may interest you: Doctors save a girl who swallowed her own hair: an incredible story
Unciti’s unique curiosity, which, despite the complexity of demonstrating the effectiveness of the treatment and preclinical tests, one of the most serious problems to complete the design of the drug was the definition of the compound of the straw, which allows the solution to be sufficiently slippery. Introduced in boxes. Once the toxicological studies have been completed, it is expected that the first clinical studies in human patients can be carried out next summer. The Cancer Research Institute at the University of Edinburgh is recognized as one of the best in the world. However, the fact that the entire preclinical package was carried out in the academic field “is very difficult. Normally this was done by the pharmaceutical industry”, explains the Spanish scientist, who emphasizes how the Nuvectis company consulted with him on everything. The new pill also involves less intrusion into the body than that caused by other more aggressive treatments such as chemotherapy. Initially, its function is not to cure cancer but to stop it, although Unciti explains that “our molecule is so selective that it recognizes the tumor and the immune system and stops destroying it.” It could be a historic moment in the fight against cancer.